-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2024-517766-41-00
4
2026-02-17
Patients with metastatic pancreatic ductal adenocarcinoma.
-
2024-519779-24-00
4
2025-11-25
VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC) syndr
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2024-511663-28-00
6
2025-09-11
Asymptomatic Child-Pugh A5 to B8 cirrhosis
-
2023-507071-21-01
1
2025-08-14
Relapsed/Refractory Multiple Myeloma
-
2024-515431-30-00
5
2025-08-14
Men treated with proctectomy for rectal cancer
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-511534-12-00
7
2025-06-10
Advanced or Metastatic Solid Tumours
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
-
2023-508634-34-00
4
2025-05-14
co-infected with the HIV-1 and HBV viruses
-
2024-515793-27-01
5
2025-04-30
HIV
-
2024-511357-22-00
4
2025-03-31
Crohn's disease
-
2024-516248-24-00
5
2025-03-28
Hereditary Angioedema
-
2023-504086-23-00
5
2025-03-27
Subjects with PBC with a non-optimal response to UDCA.
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2024-511159-16-00
6
2025-02-14
digital osteoarthritis
-
2024-510772-20-00
4
2025-02-06
Rectal cancer locally advanced with microsatellite unstable or mismatc
-
2023-509963-25-00
4
2025-01-17
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
-
2023-508626-10-00
5
2025-01-08
HIV-1 infection
-
2024-516709-22-00
10
2024-12-16
metastatic colorectal cancer carcinoma
-
2024-510981-18-00
5
2024-12-12
Multiple Myeloma
Multiple myeloma (MM) is a B cell malignancy and is o
-
2023-508724-35-00
4
2024-12-10
Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectu
-
2024-515300-39-00
4
2024-10-18
METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G